Current evidence about the association between pioglitazone and bladder cancer risk
remains conflict. We aimed to assess the risk of bladder cancer associated with the use of …

Simple Summary The roles of peroxisome proliferator-activated receptors (PPARs) in
carcinogenesis are increasingly appreciated. With the growing interest in tumor stromal …

Peroxisome proliferator-activated receptor-γ (PPAR-γ) has emerged as one of the most
extensively studied transcription factors since its discovery in 1990, highlighting its …

Peroxisome proliferator-activated receptor γ (PPARγ) belongs to the nuclear receptor
superfamily of PPARs (PPARα, PPARβ/δ, PPARγ). Numerous studies have concentrated on …

Despite the benefits of pioglitazone in the treatment of non-alcoholic fatty liver disease
(NAFLD), many treated patients continue to experience disease progression. We aimed to …

Abstract Blockade of PD-1/PD-L1 immune checkpoint could be an effective antitumor
strategy for multiple types of cancer, but it is low response rate for colorectal cancer patients …

Blockade of the programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) immune
checkpoint could increase antitumor immunotherapy for multiple types of cancer, but the …

Cancer is a disease characterized by the acquisition of a multitude of unique traits. It has
long been understood that cancer cells divert significantly from normal cell metabolism. The …

Objective Kidney transplantation is the gold standard therapeutic alternative for patients with
end‐stage renal disease; nevertheless, it is not without potential complications leading to …

Relationship on new statin use and the risk of hepatocellular carcinoma (HCC) in patients
with incident type 2 diabetes mellitus (T2DM), who might be at the risk of develo** HCC, is …